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Abstract 
Extraskeletal myxoid chondrosarcoma (EMC) is a soft tissue malignancy characterized by 
specific chromosomal abnormalities involving the TEC gene. This disease has historically 
been considered largely indolent both histologically and clinically. Rarer subsets of EMC 
exist that demonstrate aggressive histopathologic features and clinical behavior, though 
it remains unclear whether or not aggressive histopathology is predictive of outcome. 
Herein we present a case of EMC with aggressive histopathologic features that 
underwent rapid clinical progression despite initial treatment with curative intent. This 
case provides the context for a discussion of the existing literature regarding treatment, 
prognosis, pathology, and genetic/molecular features of EMC in general and aggressive 
EMC specifically. 
 
Introduction 
Extraskeletal myxoid chondrosarcoma (EMC) is a rare malignancy with distinctive 
morphologic, histologic, and immunohistochemical features. EMC has been estimated to 
comprise 2.5% of soft tissue sarcomas [1]. It occurs preferentially in men at a 2:1 ratio, 
with 50% of all cases occurring during the 5th or 6th decade of life [2]. This cancer has 
historically been described as slow-growing and late to metastasize, with 10-year survival 
rates ranging from 65 to 78% [2–4]. 
Wide local excision is the only treatment to date that offers a potential cure for EMC 
[2]. Other modalities are less effective. Radiation in doses of up to 70 Gy has been 
reported to achieve substantial reduction in tumor size in individual patients [5], but this Case Rep Oncol 2011;4:377–384 
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modality has not been associated with better outcomes in larger comparative studies [2]. 
No prospective trials have yet examined the effectiveness of radiation therapy for the 
treatment of EMC. 
There is little comparative data supporting the superiority of specific chemotherapeutic 
regimens due to the low incidence of the disease. Generally, studies have found EMC to 
have a limited response to chemotherapy. Several reports have claimed responses, but 
these have tended to be small, such as one retrospective analysis observing 1 partial 
response out of only 3 patients treated with chemotherapy [6]. Larger analyses of multiple 
different chemotherapeutic regimens have observed no responses [2, 7] and a best 
outcome of stable disease for 6 months occurring in only 25% of patients [2]. 
To our knowledge, there are no studies that demonstrate a meaningfully effective 
systemic treatment for EMC, and no large prospective trials exist. As such, outcomes for 
patients with recurrent or metastatic disease that cannot be managed by local modalities 
remain poor, despite its slow progression. Though patients may survive for years with 
systemic involvement, most patients who do not achieve a surgical cure will eventually 
succumb to their disease [8]. 
EMC with high-grade histology has been reported in rare cases in the literature. It is 
unclear whether or not there is any relationship between high-grade histology and 
aggressive clinical behavior. Herein, we report on notable clinical and histopathological 
features of a patient diagnosed with high-grade EMC, and discuss the pathologic, 
prognostic, and genetic characteristics of high-grade EMC.  
Case Report 
A 49-year-old man without a significant past medical history presented to an outside institution in 
April 2009 with a painful, enlarging left flank mass. He was treated with oral analgesics for several 
months, before computed tomography (CT) of the abdomen in September 2009 revealed a 6.2 × 4.5 cm 
solid mass in the subcutaneous tissue of the left flank. Pathological review of a biopsy in October 2009 
characterized the lesion as high grade (FNCLCC 3/3) with numerous mitotic figures. Histology was 
characterized by short, anastomosing chords and strands of ovoid cells with eosinophilic cytoplasm 
within a myxoid matrix, areas of necrosis, and nodularity (fig. 1). Immunohistochemistry was positive 
for vimentin and synaptophysin, supporting the diagnosis of EMC [4, 9]. The tumor was positive for 
EMA.  
By November 2009 the mass had grown to 7.7 × 7.8 cm, but no treatment was initiated at this time. 
In January of 2010 the patient was referred to surgical oncology at Bellevue Hospital Center (BHC); 
however, he presented to the emergency department before his scheduled appointment due to 
uncontrollable flank pain. He came to our attention at this time. 
His physical exam on arrival to BHC was notable for a large, fungating mass protruding from his 
posterior left flank at the costal margin. CT imaging showed that the mass had now grown to 12.4 × 10.4 
× 13.2 cm and was invading the musculature of the abdominal wall (fig. 2). A retrocrural lymph node 
measured 2.7 × 1.6 cm, but it was not biopsied. All other images in January 2010, including bone scan 
and brain MRI, were unremarkable and not suggestive of distant metastases. 
Surgical excision of the flank mass was performed in January 2010. The deep soft tissue margin was 
positive for malignancy. Pathology at that time showed small round blue cells (fig. 3). The morphology 
was consistent with the cellular variant for EMC, though there were none of the typical, less-cellular 
areas that, when present, allow definitive diagnosis of the cellular variant of EMC. 
Immunohistochemical staining was consistent with EMC, showing positivity for vimentin and 
synaptophysin (fig. 3d) [4, 9], focal positivity of neuron-specific enolase [9], and cytokeratin [3]. EMA, Case Rep Oncol 2011;4:377–384 
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positive in the biopsy performed in 2009, was now negative, as were S-100, desmin, GFAP, and anti-
smooth muscle actin, also consistent with this diagnosis [10]. 
Several features were suggestive of high-grade histology. There were up to 10 mitotic figures per 10 
high power fields, extensive areas of necrosis, and positive Ki-67 staining in over 95% of cells (fig. 3c). 
Cytogenetic studies did not identify the common t(9:22)(q22;q11) translocation, nor the other 
documented translocations involving 17q11, 15q21, or 3q11–12. 
The patient subsequently developed a second mass located in the right flank which was removed by 
excisional biopsy in March 2010. Pathologic features were comparable to those of the left flank mass. He 
soon developed increasing pain from a rapidly growing, locally recurrent mass in his left flank. The 
mass was visible by imaging studies and physical examination, though no biopsy of the resection bed 
was performed to confirm local recurrence. Additional imaging revealed emergence of abdominal 
lymphadenopathy (now involving the retrocrural, para-aortic, common iliac, and external iliac nodes) 
and interval development of two discrete nodules in the left adrenal gland. 
Further surgery was not deemed beneficial, and the patient underwent chemotherapy, first with one 
cycle of cisplatin and adriamycin and then with one cycle of ifosfamide, adriamycin, and vincristine, in 
April 2010. He continued to have rapid growth of the left flank mass as well as the nodal disease despite 
chemotherapy. The patient consequently deteriorated clinically and was referred for palliative radiation 
and transitioned to supportive care.  
Discussion 
Relationship between Histologic Features and Clinical Behavior 
Our developing understanding of EMC is that this disease may be less indolent than 
previously believed, given its high rates of recurrence and propensity for lung metastasis. 
The single largest study of EMC found that approximately one half of patients will 
experience local recurrence after resection, and one half will develop metastatic disease 
[3]. This is in line with findings from smaller studies that a majority of patients will 
experience some form of recurrence after surgical treatment. Drilon et al. predicted 21% 
disease-free survival at 10 years [2], and Antonescu et al. observed an overall metastasis 
rate of 65% [11]. The development of metastasis decreases the likelihood of survival [2, 3], 
but this is variable. Median survival after detection of metastasis has been reported from 
1.7 years [2] to 5.5 years [3], with individuals surviving up to 14 years after spread of EMC 
to the lung [8]. 
The vast majority of EMC cases are histologically low grade. However, several high-
grade variants have been described [11]. Given the exquisite rarity of this uncommon 
subtype of an uncommon malignancy, high-grade EMC has been difficult to study and 
remains poorly characterized [5]. 
The tumor in this case was remarkable for its aggressive histologic appearance and 
clinical behavior, both of which are atypical for EMC. The initial histology on first biopsy 
was characteristic for EMC by morphology and surface markers. However, when 
surgically excised several months later, the morphology was hypercellular with no 
resemblance to typical EMC. This transformation suggests that dedifferentiation had 
occurred, a process seen not uncommonly in aggressive malignancies. 
This patient had a number of factors – age > 45 years, large primary tumor, tumor 
located on trunk rather than extremity – that have previously been identified as poor Case Rep Oncol 2011;4:377–384 
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prognostic features for EMC [3, 4]. However, it remains unclear whether histological 
signs of aggressive behavior, such as dedifferentiation, Ki-67 staining, mitotic rate, and 
necrosis provide additional prognostic information. Anecdotally, our case is remarkably 
similar to a previously reported case of EMC, in which excision of the primary mass was 
followed by growth of a recurrent, dedifferentiated tumor and rapid clinical deterioration 
with metastatic disease [12]. 
Regardless, the clinical significance of EMC tumor grade remains controversial. Several 
small studies of EMC found that high-grade lesions were associated with a worse 
prognosis. The presence of rhabdoid cells was correlated with worse outcomes in a series 
of 36 patients [13]. A follow-up study of 20 patients with EMC found that high-grade 
tumors were associated with shorter overall survival (p = 0.045); tumor grade showed a 
trend toward increased likelihood of metastasis, but this finding was not statistically 
significant (p = 0.065) [11]. A study of 23 patients found that high cellularity, atypia, and 
the presence of focal regions of Ki-67 staining above 25% were all significant predictors of 
lower overall survival. Mitotic activity was correlated with lower overall survival but did 
not reach statistical significance [4]. A larger study of 117 patients came to different 
conclusions. Necrosis and Ki-67 labeling were significant predictors of metastasis, and 
metastasis predicted worse survival. However, neither necrosis, Ki-67 staining, high 
cellularity, mitotic activity, nor atypia were statistically significant independent predictors 
of worse prognosis [3]. 
The only report dedicated solely to high-grade EMC, a case series, observed survival 
times of 2, 3.5, and 10 months from diagnosis in the 3 patients for whom full follow-up 
was available [5]. This study is limited by the small size of its cohort, but it supports the 
conclusion that the median survival for high-grade EMC is shorter than that of lower-
grade disease. 
Genetics of EMC 
EMC genetics are typically defined by one of several chromosomal translocations 
involving the TEC gene. The t(9:22)(q22q11) translocation and/or the resultant 
EWSR1/TEC fusion product is identifiable in approximately 70% of EMC cases [14]. 
Another fusion product, RBP56/TEC, associated with translocation t(9:17)(q22;q11.2), is 
the primary mutation in an additional 15% of EMC [14]. Two additional translocations 
involving TEC have been described in single case reports. 
Interestingly, none of these translocations were found on cytogenetic analysis in this 
case. While the presence of these mutations is typically confirmatory of a diagnosis of 
EMC, there are documented cases in which no known TEC translocation was identifiable 
using conventional methods. One such study of 18 EMC cases found 12 tumors with 
EWSR1/TEC and 3 with RBP56/TEC by RT-PCR, but 3 tumors had no identifiable fusion 
products [15]. 
These results raise the possibility that other unidentified molecular abnormalities 
contribute to the pathogenesis of EMC. The two most common fusion products, 
ESWR1/TEC and RBP56/TEC, are found in only ~90% of EMCs, leaving room for 
TCF12/TEC, TGF/TEC, and potentially other undescribed molecular abnormalities. This 
is a likely occurrence in the case presented here.  Case Rep Oncol 2011;4:377–384 
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Conclusions 
EMC has been considered a largely indolent disease. Survival even after recurrence is, 
on average, prolonged, despite ineffective systemic therapy. However, there are reports in 
the literature suggesting that survival for patients who have high-grade tumors is reduced. 
Subsequent work has failed to demonstrate statistically significant prognostic values of 
individual high-grade histologic features. It is difficult to draw meaningful conclusions 
from these studies, given they are not adequately powered to demonstrate a small 
difference in prognosis between low- and high-grade disease. 
This patient’s tumor was both exquisitely high-grade by histologic criteria and 
remarkably aggressive clinically. This behavior stands in stark contrast to the indolent 
growth that, historically, has typified EMC. As others have, this report suggests a 
relationship between histologic grade and prognosis. Larger prospective case series are 
needed to illustrate a definitive correlation between histologic features and clinical 
outcomes. 
Another interesting feature in this case is the absence of the typical molecular 
abnormalities involving the TEC gene. This contributes to a body of literature that has 
demonstrated that a subset of EMC patients lacks these abnormalities by initial 
cytogenetic analysis. Some, but not all, of these patients are found to have the 
characteristic or documented abnormalities following additional testing by more sensitive 
means. The existence of a subset of patients which demonstrates no identifiable 
chromosomal or molecular abnormalities by even the most sensitive existing means 
suggests that other, unknown molecular abnormalities may contribute to EMC. Further 
study is necessary to identify and characterize other possible pathogenic mechanisms, and 
to investigate the potential for correlation between clinical behavior and the various TEC 
gene translocations. 
This case also reinforces early, wide local excision as the only effective treatment for 
EMC. In concurrence with previous studies, chemotherapy provided no observable 
response in this patient. Given the ineffectiveness of chemotherapy and radiation in the 
treatment of this disease, early and aggressive surgical resection remains the only 
opportunity for extended disease-free survival and a small chance of permanent disease 
eradication. As evidenced by prior larger patient cohorts, wide local excision in patients 
who present with localized disease offers a marginal but measurable chance for cure. 
Sadly, this patient’s disease went undetected for several months, and the window during 
which curative resection might have been possible was missed. 
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Fig. 1. Hematoxylin and eosin staining of the biopsy specimen from October 2009. Magnification: 200× 
(a), 100× (b, c). 
 
 
 
Fig. 2. a Axial and b coronal CT images from January 2010. 
 
 Case Rep Oncol 2011;4:377–384 
DOI: 10.1159/000331237 
Published online: 
August 17, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 
www.karger.com/cro   
 
 
 
383
 
Fig. 3. a, b Hematoxylin and eosin staining of the surgical specimen from January 2010. c Ki-67 stain. 
d Synaptophysin stain. Magnification: 200× (a), 400× (b), 200× (c, d). 
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